Kimberly Duff (Kim Duff)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 17

Top Topics

Hyaluronic Acid

Placebo Controlled

Top Venues

Journal of clinical immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)